Miller, R., Wilcox, R., Reneau, J., Yannakou, C., Kim, W. S., Feldman, T., Kim, Y., Khodadoust, M., Radeski, D., Gasiorowski, R., Yoon, D. H., Song, Y., Hotson, A., Mahabhashyam, S. (2025). Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL). Blood. https://doi.org/10.1182/blood-2025-778